Project Grant R00HL165026
Award Date
7/15/24
Completion Date
6/30/27
Dollars Obligated
$498K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $522,794 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Illinois to study the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The research aims to delineate how HV1 contributes to the pathogenesis of pulmonary hypertension, including examining molecular mechanisms and determining the potential for HV1...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The primary goals are to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation in vitro, examine MitoNEET expression and function during...
The federal Project Grant award of $498,000.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The primary objective of this 3-year grant, awarded on September 1, 2024, is to generate a scientific discovery program in pulmonary vascular disease research led by Dr. Woodcock at National Jewish Health in Denver, Colorado. The core research focuses on understanding the role of RNA editing, specifically the...
This $658,885 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance the fundamental understanding of the molecular mechanisms governing the development of pulmonary arterial hypertension (PAH). The research will utilize a combination of pulmonary arterial endothelial cell cultures and animal PAH models to: Determine how the protein factor Response Gene to Complement 32 (RGC-32) regulates...
The federal Project Grant award of $122,268, awarded on February 3, 2025 by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of New Mexico Health Sciences Center (UNM HSC) on the role of mitochondrial acid-sensing ion channel 1 in pulmonary hypertension. The project aims to advance scientific understanding of the mechanisms underlying cardiovascular diseases through this innovative research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $244,589 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Research Foundation For The State University Of New York (RF SUNY) to conduct research on the role of vascular smooth muscle VPS34 in pulmonary arterial hypertension (PAH). The research aims to examine the status and regulation of VPS34 in the PAH pulmonary vasculature, determine the impact of VPS34 on the proliferation and survival of PAH...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), is funding research to examine a neural circuit in the brain that contributes to the adverse cardiovascular effects of chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea. The research aims to determine how a circuit involving orexin neurons, corticotropin-releasing hormone (CRH) neurons, and neurons in the...
This federal Project Grant award for $605,678 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the prospect that hypoxia activates a pathway operating in concert with hypoxia-inducible transcription factors (HIFs) to govern the hypoxic transcriptome. Specifically, the project will...
This federal Project Grant award, titled "PULMONARY ARTERY ENDOTHELIAL CELL ENDOTYPES AND THE ROLE OF ANOIKIS RESISTANCE IN PULMONARY HYPERTENSION", is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $692,768 award will support research at Rhode Island Hospital, a division of Lifespan Corporation, to define endothelial cell dysfunction in patients with pulmonary arterial hypertension (PAH) and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $551,863 to support research on the receptor-mediated control of pulmonary ionocytes. The overall objective is to define the mechanism by which prostaglandin E2 (PGE2) balances the absorption and secretion of airway surface liquid by regulating ionocytes and secretory cells simultaneously. The research aims to establish new...